Solid Tumors

Solid tumors encompass a range of cancer types that are named for the type of cells that form them, such as ovarian, breast and lung.

Breast cancer is the most frequently diagnosed cancer in women, excluding cancers of the skin, according to the American Cancer Society (ACS). The ACS estimates that more than 232,300 new cases of invasive breast cancer are expected to be diagnosed among women in the United States during 2013 and 2,240 new cases are expected in men. About 40,000 people will die from the disease.

Bladder cancer is a type of solid tumor. The ACS estimates that more than 72,500 new cases of bladder cancer are expected to be diagnosed in the United States during 2013. More than 15,000 people will die from the disease.

Solid Tumors Clinical Trials

Brentuximab vedotin phase 2 trial for CD30-positive non-lymphoma malignancies
Single-agent trial assessing the antitumor activity and safety as well as the relationship of CD30 expression with antitumor activity of brentuximab vedotin in patients with CD30-positive non-lymphoma malignancies, including acute lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, and a number of solid tumors who have failed, refused or have been deemed ineligible for standard therapy. Study #SGN35-013
Learn more

SGN-LIV1A phase 1 trial for metastatic breast cancer
Single-agent, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. Study #SGNLVA-001
Learn more

ASG-22ME phase 1 trial for solid tumors
Single-agent, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of ASG-22ME. Study #AGS-22M6E-11-1
Learn more

ASG-15ME phase 1 trial for bladder cancer
Single-agent, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of ASG-15ME in patients with transitional cell carcinoma of the urothelium (TCCU) (cancer of the bladder, renal pelvis, ureter, or urethra). Study #AGS15E-13-1
Learn more

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com